Concern
21 plain-language articles on energy & mitochondria — the physiology, the compounds researched for it, and what the evidence actually shows.
21 articles
Mitochondrial fatigue: the energy problem doctors miss
You sleep eight hours and wake up flat. Coffee gets you to noon, then you crash. Workouts that used to feel good now feel like work for three days afterward. Labs come back normal — thyroid in range, ferritin fine, B12 fine, CBC unremarkable — and the verdict is some version of "everything looks good, try to manage your stress." If you've been told you're always tired for no reason, the reason is usually real. It just isn't on the standard panel.
NAD+ and cellular aging in plain English
If you've spent any time inside the longevity conversation, you've heard the term. NAD+ is on every supplement shelf, in every podcast, on the cover of every popular-science book about aging. What it isn't, in most of those places, is explained — what it actually does inside a cell, why levels drop with age, and why that drop matters for how you feel and how you age. Here's the plain-English version.
The chronic fatigue that isn't a diagnosis — the categories under the symptom
Your labs came back normal. Thyroid, CBC, metabolic panel — all within range. Your doctor looked at the results, looked at you, and said the thing that has become the most demoralizing sentence in modern medicine: everything looks fine. You nodded. You drove home. You got into bed at 3 p.m. not because you were lazy but because your body had nothing left, and "everything looks fine" didn't explain why or offer any path forward.
Elamipretide / Stegazo — the FDA approval for Barth syndrome and what it signals
The boy is maybe three years old and smaller than he should be. He tires quickly. His heart is enlarged on the echocardiogram — a dilated cardiomyopathy that the pediatric cardiologist has seen before in adults but rarely in a child this young. Blood work comes back with abnormally low neutrophil counts, which means infections will be harder to fight. His muscles are weak in ways that developmental milestones can't fully capture until he starts school and the gap becomes visible to everyone. The cause is a mutation on the X chromosome that his mother carried without knowing, and there is, when his family sits with the geneticist, no approved treatment to discuss. The name of what he has is Barth syndrome.
What people are reporting about Humanin
This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.
Humanin — the mitochondrial peptide that protects neurons
In 2001, in a laboratory in Tokyo, a researcher named Yuichi Hashimoto was trying to understand why some neurons survive exposure to amyloid-beta and some don't. Alzheimer's disease research at that point was already deeply invested in the amyloid hypothesis — the idea that the accumulation of amyloid-beta peptide fragments is the initiating event in the disease — but the mechanism of neuronal death was still being worked out. Hashimoto's group was screening a library of expressed sequences from the brain tissue of Alzheimer's patients, looking for something that could explain or counteract the toxicity. What they found was not what they were looking for.
ME/CFS — myalgic encephalomyelitis and the peptide conversation
You went for a thirty-minute walk on Tuesday — not a run, not a hike, a walk — and on Wednesday you couldn't get out of bed. Not tired. Not sore. Something different and worse: a systemic shutdown that feels like the body pulling the plug, a heaviness in your limbs that isn't muscle fatigue, a brain that won't sequence thoughts, a flu-like wrongness with no fever that nobody around you can see. This is what post-exertional malaise feels like. It's the defining feature of myalgic encephalomyelitis, and it's the reason that almost every intuition you have about how to recover from fatigue is exactly wrong.
Mitochondrial biogenesis — how cells build more power plants, and why it fades with age
Mitochondria were not always part of us. The leading account of their origin, championed and made rigorous by the biologist Lynn Margulis in the late 1960s against considerable resistance, is that more than a billion years ago a free-living bacterium was engulfed by a larger cell and, instead of being digested, struck a bargain. The bacterium supplied energy; the host supplied shelter and raw materials. Over deep time the guest became a permanent resident, surrendering most of its genome to the host nucleus but keeping a small loop of its own DNA — which mitochondria carry to this day. This endosymbiotic event is arguably the most consequential merger in the history of life, because the energy it unlocked made complex, large-celled organisms possible. Every breath you take feeds these descendants of an ancient bacterium, and the question of how a cell decides to build more of them sits at the center of modern metabolic and longevity science.
Mitochondrial DNA — your second genome and why it matters for aging
Most people learn it once in high school biology and never return to it: mitochondria have their own DNA. The fact gets filed away alongside the powerhouse-of-the-cell mnemonic and mostly stays there, which is a pity. Because the implications of that second genome — separate from the nuclear DNA in your chromosomes, inherited through an entirely different pathway, subject to its own distinct vulnerabilities — turn out to be one of the more important threads running through the biology of aging.
NAD+ vs MOTS-c vs SS-31 vs Humanin — the mitochondrial peptide stack, decoded
You got your labs back and your biological age came out higher than your chronological age. Or the fatigue is real — not the kind that coffee fixes, not the kind that a good night's sleep fully resolves — a deeper, structural tiredness that has started to feel like a baseline rather than a symptom. Or you've been researching longevity seriously and you've arrived at the mitochondria, because the research keeps pointing there: cellular energy, oxidative stress, the gradual degradation of the organelles that power everything else. You've encountered four names being discussed — NAD+, MOTS-c, SS-31, Humanin — and you want to understand what each actually does, why they're being discussed together, and whether the combination logic holds up.
MOTS-c for athletic performance and the exercise mimetic question
You're thirty-eight, or forty-two, and the training hasn't changed that much. You're still putting in the hours. You're still doing the things that worked. But the baseline has shifted — the recovery takes longer than it used to, the metabolic flexibility that let you run hard and bounce back has grown sluggish, and the same effort that used to leave you feeling sharp now leaves you grinding through the back half of the week. Your body has changed the math on you without telling you what changed.
What people are reporting about MOTS-c
This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.
MOTS-c in longevity stacks — what's being explored
The longevity protocol world has a stacking problem. Not a problem in the sense that stacking is necessarily wrong — combining compounds that address different mechanisms is conceptually sound in medicine — but a problem in the sense that the reasoning often runs backward. The aspiration comes first. The compounds follow. The mechanism gets retrofitted to justify what was already going to happen. When you're dealing with compounds that have thin human evidence and strong preclinical data, this pattern matters enormously, because it's the difference between a rationally assembled protocol and an expensive bet dressed up in biological language.
MOTS-c in plain English — mitochondrial-derived peptides explained
Your mitochondria are not quiet. They're not just burning fuel and staying out of the way. They're running a continuous metabolic read on the cell's energy state and broadcasting updates — and those updates, it turns out, include peptides that circulate through the body and communicate with tissues that have nothing to do with where the mitochondria physically sit. MOTS-c is one of those peptides. Understanding what it actually does requires starting with what the cell does when energy runs low.
MOTS-c — the peptide your mitochondria write themselves
In 2015, a research team at the University of Southern California published a paper in Cell Metabolism that quietly changed the way biologists had to think about the mitochondrion. The paper was not loudly announced outside specialist circles. It didn't generate the cultural noise that cancer immunotherapy or CRISPR news generated that same year. But what Pinchas Cohen, Changhan Lee, and their colleagues described was a genuine reclassification — a finding that required updating a story about cellular biology that had been told, largely without revision, since the 1960s.
NAD+ and CD38 — why supplementing alone might not be enough
You start taking NMN. Your NAD+ levels come up, at least on a blood test. Three months later, maybe six, the effect seems to blunt. You're still taking it, the dose hasn't changed, but something about the initial lift has flattened. Maybe you increase the dose. Maybe it helps. Maybe it doesn't. You've entered a conversation that the supplement marketing doesn't prepare you for: that raising NAD+ levels is not just a question of what you put in, but of what's consuming it on the other end — and that consumption is running faster as you age.
Peptides for energy and fatigue — what research has explored at the cellular and systemic level
You don't feel stressed the way you feel hungry. Chronic fatigue doesn't go away when the stressful thing ends. It is there in the morning before anything has happened. It is there after a full night of sleep that didn't restore anything. The coffee works for an hour and then the tiredness reasserts itself, heavier than before. It is not dramatic — fatigue rarely is. It is a narrowing. The things you used to do without thinking about them now require decisions. You lie down in the afternoon not because you want to but because the alternative is worse.
SS-31 and cardiolipin — the mitochondrial membrane story
The power goes out and the neighborhood goes dark. You don't notice everything that ran on electricity until it stops running. The same logic applies to the mitochondria in your cells — not metaphorically, but mechanically. When the inner architecture of a mitochondrion begins to fail, it isn't one function that drops out. It's everything that electricity powers.
SS-31 in mitochondrial myopathy and heart failure research
The men who design drugs for heart failure have one of the more humbling jobs in medicine. Heart failure affects tens of millions of people worldwide. The field has produced real breakthroughs — ACE inhibitors, beta-blockers, SGLT2 inhibitors — and yet significant numbers of patients continue to progress toward transplant or death despite optimal medical therapy. When a new mechanism comes along, the desperation to apply it broadly is understandable. The history of cardiology is littered with compounds that worked brilliantly in animal models and failed in human trials. The cautionary lesson keeps being delivered and keeps being partially ignored.
The coffee dependence that wasn't there before
You used to drink one cup. Maybe two on busy mornings, but one was usually enough. Somewhere in the last few years that changed — you couldn't say exactly when — and now the arithmetic is different. Three cups to feel functional. Skip the morning coffee and by ten a.m. there's a headache sitting behind your eyes and an irritability that isn't quite you. The afternoon cup, which you used to skip without thinking about it, has become non-negotiable. You've tried cutting back. The first day is manageable. By the second morning you feel like you're moving through syrup.
The cardio that feels harder — when the same effort registers as more work
You've been running this route for three years. You know it — the grade on the first half-mile, the way the second mile opens up, how long the hill takes when your legs are fresh. The pace that used to feel like an easy conversation now has you monitoring your breathing. Your heart rate at what you've always called an easy effort is running ten, sometimes fifteen beats higher than it used to. You finish and the recovery takes longer. You used to run on Tuesday and feel ready again by Thursday. Now Friday is more honest. The bike ride you've done weekly all summer requires a day more. Your body is technically doing the same thing. It doesn't feel the same at all.